Anika Therapeutics, Inc. SEC filings ANIK

Anika Therapeutics, Inc. has 1,004 filings in SEC EDGAR's recent list, going back to Dec 19, 2003. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 29, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jul 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Anika Therapeutics, Inc. SEC filings
Form Description Filed Period
144 Notice of proposed sale Aug 7, 2026 —
4 Insider transaction Aug 5, 2026 Aug 3, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 31, 2026 —
S-8 Employee stock plan registration Jul 29, 2026 —
10-Q Quarterly report Jul 29, 2026 Jun 30, 2026
8-K Current report
Results of operations
Jul 29, 2026 Jul 29, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 17, 2026 —
8-K Current report
Material agreement, New debt
Jul 14, 2026 Jul 10, 2026
4 Insider transaction Jun 23, 2026 Jun 18, 2026
4 Insider transaction Jun 23, 2026 Jun 18, 2026
4 Insider transaction Jun 23, 2026 Jun 18, 2026
4 Insider transaction Jun 23, 2026 Jun 18, 2026
4 Insider transaction Jun 23, 2026 Jun 18, 2026
8-K Current report
Officer or director change, Shareholder vote results
Jun 23, 2026 Jun 18, 2026
DEFA14A Additional proxy material Jun 8, 2026 —
4 Insider transaction Jun 5, 2026 Jun 3, 2026
DEFA14A Additional proxy material Jun 1, 2026 —
4 Insider transaction May 4, 2026 May 1, 2026
4 Insider transaction Apr 30, 2026 Apr 30, 2026
10-Q Quarterly report Apr 30, 2026 Mar 31, 2026
SCHEDULE 13G Ownership over 5% (passive) Apr 29, 2026 —
8-K Current report
Results of operations, Officer or director change
Apr 29, 2026 Apr 24, 2026
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 18, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Mar 26, 2026 —
4 Insider transaction Mar 23, 2026 Mar 19, 2026
4 Insider transaction Mar 17, 2026 Mar 14, 2026
4 Insider transaction Mar 17, 2026 Mar 14, 2026
4 Insider transaction Mar 17, 2026 Mar 14, 2026
4 Insider transaction Mar 17, 2026 Mar 14, 2026
4 Insider transaction Mar 11, 2026 Mar 9, 2026
4 Insider transaction Mar 11, 2026 Mar 9, 2026
4 Insider transaction Mar 11, 2026 Mar 9, 2026
10-K Annual report Mar 3, 2026 Dec 31, 2025
8-K Current report
Results of operations, Officer or director change
Feb 26, 2026 Feb 26, 2026
4 Insider transaction Feb 3, 2026 Feb 1, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Jan 27, 2026 —
8-K Current report
Results of operations, Officer or director change
Jan 8, 2026 Jan 7, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Jan 8, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 21, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 7, 2025 —
S-8 Employee stock plan registration Nov 5, 2025 —
10-Q Quarterly report Nov 5, 2025 Sep 30, 2025
8-K Current report
Results of operations, Other events
Nov 5, 2025 Nov 5, 2025
SCHEDULE 13G Ownership over 5% (passive) Oct 17, 2025 —
10-Q Quarterly report Jul 30, 2025 Jun 30, 2025
8-K Current report
Results of operations
Jul 30, 2025 Jul 30, 2025
8-K Current report
Regulation FD disclosure
Jul 30, 2025 Jul 30, 2025
UPLOAD Letter from the SEC Jul 24, 2025 —
CORRESP Letter to the SEC Jul 17, 2025 —
4 Insider transaction Jun 24, 2025 Jun 20, 2025
4 Insider transaction Jun 24, 2025 Jun 20, 2025
4 Insider transaction Jun 24, 2025 Jun 20, 2025
4 Insider transaction Jun 24, 2025 Jun 20, 2025
4 Insider transaction Jun 24, 2025 Jun 20, 2025
4 Insider transaction Jun 24, 2025 Jun 20, 2025
4 Insider transaction Jun 24, 2025 Jun 20, 2025
4 Insider transaction Jun 24, 2025 Jun 20, 2025
8-K Current report
Officer or director change, Shareholder vote results
Jun 24, 2025 Jun 20, 2025
UPLOAD Letter from the SEC Jun 18, 2025 —
4 Insider transaction Jun 5, 2025 Jun 3, 2025
10-Q Quarterly report May 9, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 9, 2025 May 9, 2025
ARS Annual report to shareholders Apr 28, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 28, 2025 —
DEF 14A Proxy statement Apr 28, 2025 Jun 20, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 17, 2025 —
3 Initial insider ownership Apr 11, 2025 Apr 5, 2025
8-K Current report
Officer or director change
Apr 10, 2025 Apr 4, 2025
4 Insider transaction Mar 18, 2025 Mar 14, 2025
4 Insider transaction Mar 18, 2025 Mar 14, 2025
4 Insider transaction Mar 18, 2025 Mar 14, 2025
4 Insider transaction Mar 18, 2025 Mar 14, 2025
10-K Annual report Mar 17, 2025 Dec 31, 2024
4 Insider transaction Mar 13, 2025 Mar 11, 2025
4 Insider transaction Mar 13, 2025 Mar 11, 2025
4 Insider transaction Mar 13, 2025 Mar 11, 2025
8-K Current report
Results of operations
Mar 12, 2025 Mar 12, 2025
4 Insider transaction Mar 11, 2025 Mar 10, 2025
4 Insider transaction Mar 11, 2025 Mar 10, 2025
4 Insider transaction Mar 11, 2025 Mar 10, 2025
8-K Current report
Acquisition or sale of assets, Regulation FD disclosure
Mar 11, 2025 Mar 7, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 5, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Jan 23, 2025 —
SC 13G/A Amended ownership over 5% (passive) Nov 8, 2024 —
10-Q Quarterly report Nov 4, 2024 Sep 30, 2024
8-K Current report
Results of operations
Oct 31, 2024 Oct 31, 2024
8-K Current report
Acquisition or sale of assets, Regulation FD disclosure
Oct 31, 2024 Oct 31, 2024
SC 13G/A Amended ownership over 5% (passive) Oct 23, 2024 —
4 Insider transaction Oct 4, 2024 Oct 1, 2024
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 8, 2024 Aug 8, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
4 Insider transaction Jul 11, 2024 Jul 9, 2024
8-K Current report
Shareholder vote results
Jul 11, 2024 Jul 9, 2024
DEFA14A Additional proxy material Jun 25, 2024 —
ARS Annual report to shareholders Jun 11, 2024 Dec 31, 2023
DEF 14A Proxy statement Jun 11, 2024 Jul 9, 2024
4 Insider transaction Jun 5, 2024 Jun 3, 2024
4 Insider transaction Jun 5, 2024 Jun 3, 2024
4 Insider transaction Jun 5, 2024 Jun 3, 2024
3 Initial insider ownership Jun 5, 2024 May 28, 2024
3 Initial insider ownership Jun 5, 2024 Jun 3, 2024
3 Initial insider ownership Jun 5, 2024 May 28, 2024
S-8 Employee stock plan registration May 31, 2024 —
SC 13D/A Amended ownership over 5% (active) May 30, 2024 —
8-K Current report
Material agreement, Officer or director change, Regulation FD disclosure
May 28, 2024 May 28, 2024
10-Q Quarterly report May 8, 2024 Mar 31, 2024
8-K Current report
Officer or director change
May 8, 2024 May 2, 2024
8-K Current report
Results of operations
May 8, 2024 May 8, 2024
10-K/A Amended annual report Apr 26, 2024 Dec 31, 2023
SC 13G/A Amended ownership over 5% (passive) Apr 5, 2024 —
4 Insider transaction Mar 19, 2024 Mar 15, 2024
4 Insider transaction Mar 19, 2024 Mar 15, 2024
4 Insider transaction Mar 19, 2024 Mar 15, 2024
4 Insider transaction Mar 19, 2024 Mar 15, 2024
10-K Annual report Mar 15, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 13, 2024 Mar 13, 2024
4 Insider transaction Mar 12, 2024 Mar 11, 2024
4 Insider transaction Mar 12, 2024 Mar 11, 2024
4 Insider transaction Mar 12, 2024 Mar 11, 2024
4 Insider transaction Mar 12, 2024 Mar 11, 2024
SC 13D/A Amended ownership over 5% (active) Mar 6, 2024 —
8-K Current report
Officer or director change
Feb 26, 2024 Feb 24, 2024
SC 13G/A Amended ownership over 5% (passive) Feb 13, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 9, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 9, 2024 —
SC 13G/A Amended ownership over 5% (passive) Jan 24, 2024 —
SC 13G/A Amended ownership over 5% (passive) Jan 22, 2024 —
S-8 POS Filing Jan 22, 2024 —
S-8 Employee stock plan registration Jan 19, 2024 —
3/A Filing Jan 12, 2024 Jun 19, 2023
10-Q Quarterly report Nov 3, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 2, 2023 Nov 2, 2023
SC 13G/A Amended ownership over 5% (passive) Oct 6, 2023 —
4 Insider transaction Oct 3, 2023 Oct 1, 2023
8-K Current report
Regulation FD disclosure
Sep 21, 2023 Sep 21, 2023
SC 13D/A Amended ownership over 5% (active) Sep 11, 2023 —
SC 13D Ownership over 5% (active) Aug 17, 2023 —
4 Insider transaction Aug 11, 2023 Aug 10, 2023
S-8 Employee stock plan registration Aug 8, 2023 —
10-Q Quarterly report Aug 8, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 8, 2023 Aug 8, 2023
3 Initial insider ownership Jun 26, 2023 Jun 19, 2023
8-K Current report
Officer or director change, Shareholder vote results
Jun 21, 2023 Jun 14, 2023
4 Insider transaction Jun 16, 2023 Jun 14, 2023
4 Insider transaction Jun 16, 2023 Jun 14, 2023
4 Insider transaction Jun 16, 2023 Jun 14, 2023
4 Insider transaction Jun 16, 2023 Jun 14, 2023
4 Insider transaction Jun 16, 2023 Jun 14, 2023
4 Insider transaction Jun 16, 2023 Jun 14, 2023
4 Insider transaction Jun 16, 2023 Jun 14, 2023
10-Q Quarterly report May 9, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 9, 2023 May 9, 2023
ARS Annual report to shareholders May 1, 2023 Dec 31, 2022
DEFA14A Additional proxy material May 1, 2023 —
DEF 14A Proxy statement May 1, 2023 —
4 Insider transaction Apr 28, 2023 Apr 26, 2023
8-K Current report
Other events
Apr 28, 2023 Apr 24, 2023
PRER14A Filing Apr 25, 2023 —
4 Insider transaction Apr 17, 2023 Apr 13, 2023
3 Initial insider ownership Apr 17, 2023 Apr 13, 2023
8-K Current report
Material agreement, Officer or director change, Regulation FD disclosure
Apr 13, 2023 Apr 13, 2023
PRRN14A Anika therapeutics, inc. Apr 6, 2023 —
UPLOAD Letter from the SEC Apr 5, 2023 —
CORRESP Letter to the SEC Apr 5, 2023 —
PRER14A Filing Apr 5, 2023 —
UPLOAD Letter from the SEC Apr 4, 2023 —
PREC14A Anika therapeutics, inc. Mar 30, 2023 —
DEFA14A Additional proxy material Mar 27, 2023 —
PREC14A Filing Mar 27, 2023 —
10-K Annual report Mar 16, 2023 Dec 31, 2022
4 Insider transaction Mar 14, 2023 Mar 10, 2023
4 Insider transaction Mar 14, 2023 Mar 10, 2023
4 Insider transaction Mar 14, 2023 Mar 10, 2023
4 Insider transaction Mar 10, 2023 Mar 9, 2023
4 Insider transaction Mar 10, 2023 Mar 9, 2023
4 Insider transaction Mar 10, 2023 Mar 9, 2023
4 Insider transaction Mar 7, 2023 Mar 4, 2023
8-K Current report
Results of operations
Mar 6, 2023 Mar 6, 2023
DFAN14A Anika therapeutics, inc. Feb 21, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 10, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 10, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 9, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 8, 2023 —
SC 13G/A Amended ownership over 5% (passive) Jan 26, 2023 —
SC 13G Ownership over 5% (passive) Jan 20, 2023 —
10-Q Quarterly report Nov 9, 2022 Sep 30, 2022
8-K Current report
Results of operations
Nov 8, 2022 Nov 8, 2022
8-K Current report
Other events
Nov 1, 2022 Nov 1, 2022
SC 13G Ownership over 5% (passive) Oct 7, 2022 —
4 Insider transaction Aug 11, 2022 Aug 10, 2022

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
ANIK (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Bedford, MA
SEC filer status
Accelerated filer
SEC CIK
898437
Former names
ANIKA THERAPEUTICS INC (until Mar 13, 2014); ANIKA RESEARCH INC (until Nov 27, 1996)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.